|02/17/17||AbbVie Announces $5 Billion Increase to Stock Repurchase Program|
|NORTH CHICAGO, Ill., Feb. 17, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program.
Purchases may be made from time to time in management's discretion. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time.
AbbVie is a global, research-based biopharmaceutical company ... |
|02/16/17||AbbVie Declares Quarterly Dividend|
|NORTH CHICAGO, Ill., Feb. 16, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.64 per share.
The cash dividend is payable May 15, 2017 to stockholders of record at the close of business on April 13, 2017.
Since the company's inception in 2013, AbbVie has increased its dividend by 60 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their div... |
|02/15/17||AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference|
|NORTH CHICAGO, Ill., Feb. 15, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017. William Chase, executive vice president and chief financial officer, will present at 8:20 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
|01/27/17||AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results|
|- Reports Full-Year Diluted EPS of $3.63 on a GAAP Basis; Adjusted Diluted EPS of $4.82, Reflecting Growth of 12.4 Percent
- Delivers Full-Year Net Revenues of $25.638 Billion on a GAAP Basis; Adjusted Net Revenues of $25.560 Billion Grew 13.3 Percent on an Operational Basis
- Full-Year Global Humira Sales of $16.078 Billion Increased 16.1 Percent on an Operational Basis
- Full-Year Global IMBRUVICA Net Revenues Exceeded $1.8 Billion
- Reports Fourth-Quarter Diluted EPS of $0.85 on a... |
|01/10/17||AbbVie to Host Fourth-Quarter 2016 Earnings Conference Call|
|NORTH CHICAGO, Ill., Jan. 10, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its Fourth-Quarter 2016 financial results on Friday, January 27, 2017.
AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website http://investors.abbvie.com. An archived edition of the session will be available later that day.
AbbVie is a global, research-based biopharmaceutical c... |